ClinicalTrials.gg
Sign In

Neurofibrosarcoma clinical trials

The registry lists 98 studies for Neurofibrosarcoma across more than 10 countries. 23 are recruiting or about to start. 19 of them are mainly about Neurofibrosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Neurofibrosarcoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
44
Recruiting
18
Terminated
10
Status unknown
9
Active, not recruiting
9
Withdrawn
3

Phase

Phase 2
57
Phase 1
35
Phase 3
11
Early Phase 1
1

Where

United States
63
Belgium
11
United Kingdom
9
Germany
9
France
8
Canada
8

Who runs them

National Cancer Institute (NCI) (13) · European Organisation for Research and Treatment of Cancer - EORTC (13) · Memorial Sloan Kettering Cancer Center (5) · Sarcoma Alliance for Research through Collaboration (5) · Novartis Pharmaceuticals (2) · OHSU Knight Cancer Institute (2) · St. Jude Children's Research Hospital (2) · Tango Therapeutics, Inc. (2)

What is being tested here

Drugs under test in Neurofibrosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Selinexor204
Navlimetostat202
Doxorubicin1510
Ifosfamide168
Pazopanib115
Alrizomadlin102
AZD 6244102
Liposomal doxorubicin102
RO5126766101
Defactinib101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Immune checkpoint inhibitors 2 open · Alkylating agents 1 open · mTOR inhibitors 3

Coming up

0phase 3 studies under way
7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Who these studies take

Of the 18 Neurofibrosarcoma studies recruiting now, 10 (56%) set no upper age limit and 5 (28%) stop at 75 or younger. 11 (61%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 18
AgeWomenMen
107 (39%)7 (39%)
1818 (100%)18 (100%)
3016 (89%)16 (89%)
4015 (83%)15 (83%)
5015 (83%)15 (83%)
6515 (83%)15 (83%)
7514 (78%)14 (78%)
8513 (72%)13 (72%)

Across all 98 studies, recruiting or not: 22% stop at 75 or younger and 14% at 65; 50% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neurofibrosarcoma studies take

Of 18 phase 2 interventional studies under Neurofibrosarcoma, half reached primary completion within 41 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 241 mo32–80 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 98. Browse all 98 → or search them.